Table 3.
Pharmacists' decision to report hypothetical ADRs in line with Committee on Safety of Medicines/Medicines Control Agency reporting criteria
| Reaction1 | Yes | No | Don’t know |
|---|---|---|---|
| Jaundice with frusemide (Yes)2 | 198 (72.5%) | 34 (12.5%) | 41 (15.0%) |
| Nausea with montelukast3 (Yes) | 192 (70.1%) | 51 (18.6%) | 31 (11.3%) |
| Headache with venlafaxine3 (Yes) | 129 (47.6%) | 104 (38.4%) | 38 (14.0%) |
| Thrombocytopaenia with heparin (Yes) | 115 (41.5%) | 138 (49.8%) | 24 (8.7%) |
| Gastrointestinal bleed with diclofenac (Yes) | 92 (33.1%) | 169 (60.8%) | 17 (6.1%) |
| Cold extremities with β-adrenoceptor blockers (No) | 1 (0.4%) | 265 (96.0%) | 10 (3.6%) |
1
Number of responses from pharmacists varied from 273 to 278.
2
Responses in brackets refer to standard CSM reporting criteria in the UK.
3
Montelukast and venlafaxine were under intensive monitoring at the time of the survey (as indicated by ▾) although this was not indicated on the questionnaire.